STAAR Surgical Company - 10-Q Summary (Period Ended June 27, 2008)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR Surgical Company for the three and six months ended June 27, 2008. STAAR develops, manufactures, and sells visual implants and ophthalmic products, primarily intraocular lenses (IOLs) for cataract surgery and the Visian ICL for refractive surgery. The company operates manufacturing facilities in the U.S., Switzerland, and Japan, with distribution in approximately 50 countries. A significant event during the period was the full acquisition of the remaining 50% interest in its Japanese joint venture, Canon Staar, which became a wholly-owned subsidiary named STAAR Japan, Inc. on December 29, 2007.
Key Financial Metrics
| Metric | Three Months Ended June 27, 2008 |
Six Months Ended June 27, 2008 |
Six Months Ended June 29, 2007 |
|---|---|---|---|
| Net Sales | $20.7 million | $38.6 million | $29.8 million |
| Gross Profit | $11.5 million | $19.3 million | $14.5 million |
| Gross Margin | 55.8% | 49.9% | 48.7% |
| Operating Loss | $(2.0) million | $(10.7) million | $(6.9) million |
| Net Loss | $(2.5) million | $(11.5) million | $(7.9) million |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.39) | $(0.29) |
| Cash and Cash Equivalents | $8.9 million (End of Period) | N/A | |
| Net Cash Used in Operating Activities | N/A | $(6.1) million | $(7.0) million |
| Total Debt (Line of Credit + Notes) | $6.1 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 38% for the quarter and 29% year-to-date compared to the prior year. This growth was driven primarily by the consolidation of STAAR Japan sales ($3.3 million for the quarter, $6.1 million YTD) and favorable currency fluctuations ($1.1 million for the quarter, $1.9 million YTD).
- Profitability: Despite revenue growth, the company reported a net loss of $11.5 million for the six months ended June 27, 2008, compared to $7.9 million in the prior year. The increase in loss was significantly impacted by a one-time $3.9 million non-cash charge for the "Loss on settlement of pre-existing distribution arrangement" related to the STAAR Japan acquisition.
- Operating Expenses: Marketing and selling expenses increased 23% YTD, and R&D expenses increased 26% YTD, largely due to the inclusion of STAAR Japan's costs and increased spending to drive sales growth.
- U.S. Sales: U.S. net sales decreased 5% YTD, driven by a 12% decline in cataract product sales, partially offset by a 21% increase in refractive product sales (Visian ICL).
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management's primary strategic goals are to improve cash flow, increase U.S. sales (specifically reversing cataract declines and growing refractive sales), successfully integrate STAAR Japan, and maintain international growth. The company is implementing cost-cutting measures targeting $3.5 million in annualized savings and an additional $2-3 million in global cost reductions. Management believes the company has sufficient cash to meet funding requirements through the first quarter of 2009 but may need additional financing if losses continue.
Regulatory Risks: The FDA has placed an "integrity hold" on the application for the Toric ICL (TICL) pending a third-party audit of clinical data and quality systems. Approval of the TICL is critical for U.S. refractive growth. Additionally, the company faces reputational challenges from past FDA compliance findings.
Legal Contingencies: The company is defending against lawsuits filed by former regional manufacturer's representatives (Moody and Parallax) claiming damages totaling $80 million. STAAR believes these claims are without merit and has filed cross-complaints, but litigation costs could be substantial and unrecoverable.
Market Risks: An economic downturn could reduce demand for elective refractive surgery. Negative publicity regarding LASIK complications could either boost interest in the Visian ICL as an alternative or depress demand for all refractive surgery.
Key Facts for Investor Verification
- Acquisition Impact: Verify the sustainability of revenue growth from STAAR Japan now that the initial consolidation effects and one-time settlement charges are accounted for.
- TICL Approval Status: Monitor the progress of the third-party audit and FDA review for the Toric ICL, as approval is essential for U.S. refractive strategy.
- Liquidity Position: Assess the company's ability to fund operations through Q1 2009 given the history of negative operating cash flows and the need for potential future capital raises.
- U.S. Cataract Trends: Track whether new product introductions (aspheric IOLs, nanoPOINT injector) can reverse the long-term decline in U.S. cataract market share.
- Legal Exposure: Review developments in the Moody and Parallax litigation, as a negative outcome could result in material financial harm.